Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
899 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT05655260 | PErsonalized TReatment for Endometrial Carcinoma(PETREC) | recruiting | N/A | 300 | University of HelsinkiOTHER | 1 |
| Dec 6, 2024 |
| clinicaltrials |
| NCT01276574 | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT(Mupet) | active not recruiting | — | 150 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05212103 | PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9(CANSI) | enrolling by invitation | — | 30 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03350529 | MRI Guided Transurethral HIFU for Various Prostate Diseases(HIFU-PRO) | completed | N/A | 87 | Turku University HospitalOTHER_GOV | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06701058 | Active MMP-8 in Oral Fluid for the Detection of Oral and Oropharyngeal Cancer | completed | — | 107 | Helsinki University Central HospitalOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | active not recruiting | Phase 2 / Phase 3 | 140 | Oslo University HospitalOTHER | 4 | Nov 20, 2024 | clinicaltrials |
| NCT06044623 | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients(IMPORTANT) | recruiting | Phase 3 | 495 | Region Örebro CountyOTHER | 6 | Nov 19, 2024 | clinicaltrials |
| NCT01084252 | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 351 | SanofiINDUSTRY | 17 | Nov 1, 2024 | clinicaltrials |
| NCT06654570 | Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial | completed | Phase 2 | 20 | Helsinki University Central HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT03721978 | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | completed | Phase 3 | 203 | Inovio PharmaceuticalsINDUSTRY | 10 | Oct 17, 2024 | clinicaltrials |
| NCT05363072 | A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland. | completed | — | 1,112 | PfizerINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04571840 | Prostate Imaging Using MRI +/- Contrast Enhancement(PRIME) | active not recruiting | N/A | 500 | University College, LondonOTHER | 15 | Sep 23, 2024 | clinicaltrials |
| NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma(POLAR BEAR) | recruiting | Phase 3 | 300 | Nordic Lymphoma GroupNETWORK | 7 | Sep 19, 2024 | clinicaltrials |
| NCT04267081 | Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening(VenEx) | completed | Phase 2 | 104 | Helsinki University Central HospitalOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02825628 | Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)(CRPC) | completed | Phase 2 | 55 | DexTech Medical ABINDUSTRY | 4 | Aug 29, 2024 | clinicaltrials |
| NCT02348489 | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | completed | Phase 3 | 815 | Astex Pharmaceuticals, Inc.INDUSTRY | 24 | Aug 27, 2024 | clinicaltrials |
| NCT03402841 | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients(OPINION) | completed | Phase 3 | 279 | AstraZenecaINDUSTRY | 19 | Aug 21, 2024 | clinicaltrials |
| NCT05223673 | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer(COLSTAR) | terminated | Phase 3 | 7 | Institut de Recherches Internationales ServierOTHER | 6 | Aug 20, 2024 | clinicaltrials |
| NCT05947903 | Validation of the European Oncology Quality of Life Toolkit | unknown | — | 4,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 32 | Aug 20, 2024 | clinicaltrials |
| NCT00469417 | Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma | completed | Phase 3 | 120 | Galderma R&DINDUSTRY | 7 | Aug 19, 2024 | clinicaltrials |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 3 | 104 | Hinova Pharmaceuticals USA, Inc.INDUSTRY | 14 | Aug 19, 2024 | clinicaltrials |
| NCT05572801 | NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer | recruiting | N/A | 400 | Aarhus University HospitalOTHER | 4 | Aug 14, 2024 | clinicaltrials |
| NCT03859427 | A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma(ARROW2) | completed | Phase 3 | 454 | AmgenINDUSTRY | 17 | Aug 13, 2024 | clinicaltrials |
| NCT01660451 | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas | completed | Phase 2 | 227 | BayerINDUSTRY | 25 | Jul 17, 2024 | clinicaltrials |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas(GAMMA) | completed | Phase 3 | 800 | NantCell, Inc.INDUSTRY | 32 | Jul 16, 2024 | clinicaltrials |
| NCT05159245 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE) | recruiting | Phase 2 | 250 | Helsinki University Central HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT02487524 | Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer | completed | N/A | 402 | Helsinki University Central HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT03293173 | Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis(Bio-CHIC) | unknown | Phase 2 | 120 | Nordic Lymphoma GroupNETWORK | 4 | Jun 21, 2024 | clinicaltrials |
| NCT03610724 | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients(BIANCA) | completed | Phase 2 | 34 | Novartis PharmaceuticalsINDUSTRY | 14 | Jun 20, 2024 | clinicaltrials |
| NCT03638440 | Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.(NACASY) | completed | — | 183 | Kyowa Kirin Pharmaceutical Development LtdINDUSTRY | 10 | Jun 17, 2024 | clinicaltrials |
| NCT03444259 | Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients(CAREBANK) | active not recruiting | — | 1,001 | University of TurkuOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT04142372 | Tissue Microarray of Hematological Malignancies(HemaTMA) | active not recruiting | — | 5,000 | Tampere University HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05257577 | Factors Influencing Breast Cancer Resection Volumes And Their Impact on Treatment Outcome (FIBRATIO)(FIBRATIO) | active not recruiting | — | 220 | Tampere University HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT01906866 | Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities | completed | Phase 3 | 125 | Neurim Pharmaceuticals Ltd.INDUSTRY | 5 | Apr 23, 2024 | clinicaltrials |
| NCT06063343 | Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145 | completed | Phase 1 | 50 | Novakand Pharma ABINDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT01397916 | Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)(KLL3) | completed | — | 73 | Tampere University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05446779 | Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death(SuddenDeath) | active not recruiting | — | 400 | Helsinki University Central HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT03267030 | Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase | completed | Phase 2 | 55 | Birgitte Klug AlbertsenOTHER | 6 | Mar 15, 2024 | clinicaltrials |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | terminated | Phase 2 | 190 | Swiss Cancer InstituteOTHER | 6 | Mar 13, 2024 | clinicaltrials |
| NCT04392505 | Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study(DART) | active not recruiting | Phase 2 | 100 | Oslo University HospitalOTHER | 4 | Feb 29, 2024 | clinicaltrials |
| NCT04653181 | Preoperative i.v. Iron Substitution in Patients With Colon Cancer(PREFECO) | unknown | N/A | 514 | Helsinki University Central HospitalOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT02222272 | Effect of 2nd Gen TKI in CML | completed | — | 432 | European Society for Blood and Marrow TransplantationNETWORK | 9 | Feb 20, 2024 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials